AIT Therapeutics (OTCMKTS:AITB) was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating in a note issued to investors on Wednesday.
Separately, Zacks Investment Research raised AIT Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, December 24th.
AITB stock opened at $4.85 on Wednesday. The firm has a market cap of $42.13 million, a PE ratio of -1.61 and a beta of -0.32. AIT Therapeutics has a twelve month low of $2.05 and a twelve month high of $5.50.
AIT Therapeutics (OTCMKTS:AITB) last released its earnings results on Wednesday, February 13th. The company reported $0.11 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.32. On average, research analysts forecast that AIT Therapeutics will post -0.78 EPS for the current year.
AIT Therapeutics Company Profile
AIT Therapeutics, Inc, a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) delivery systems to treat respiratory and other diseases. Its NO delivery systems are used for the treatment of pulmonary hypertension of the newborn, bronchiolitis, and nontuberculous mycobacteria.
Featured Story: Debt-To-Equity Ratio
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for AIT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.